Metabolite transfer with the fermentation product 2,3-butanediol enhances virulence by Pseudomonas aeruginosa
The respiratory tract of cystic fibrosis (CF) patients harbor persistent microbial communities (CF airway microbiome) with Pseudomonas aeruginosa emerging as a dominant pathogen. Within a polymicrobial infection, interactions between co-habitant microbes can be important for pathogenesis, but even w...
Gespeichert in:
Veröffentlicht in: | The ISME Journal 2014-06, Vol.8 (6), p.1210-1220 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The respiratory tract of cystic fibrosis (CF) patients harbor persistent microbial communities (CF airway microbiome) with
Pseudomonas aeruginosa
emerging as a dominant pathogen. Within a polymicrobial infection, interactions between co-habitant microbes can be important for pathogenesis, but even when considered, these interactions are not well understood. Here, we show with
in vitro
experiments that, compared with glucose, common fermentation products from co-habitant bacteria significantly increase virulence factor production, antimicrobial activity and biofilm formation of
P. aeruginosa
. The maximum stimulating effect was produced with the fermentation product 2,3-butanediol, which is a substrate for
P. aeruginosa
, resulting in a metabolic relationship between fermenters and this pathogen. The global transcription regulator LasI LasR, which controls quorum sensing, was upregulated threefold with 2,3-butanediol, resulting in higher phenazine and exotoxin concentrations and improved biofilm formation. This indicates that the success of
P. aeruginosa
in CF airway microbiomes could be governed by the location within the food web with fermenting bacteria. Our findings suggest that interbacterial metabolite transfer in polymicrobial infections stimulates virulence of
P. aeruginosa
and could have a considerable impact on disease progression. |
---|---|
ISSN: | 1751-7362 1751-7370 |
DOI: | 10.1038/ismej.2013.232 |